Compile Data Set for Download or QSAR
Report error Found 240 Enz. Inhib. hit(s) with all data for entry = 2588
TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372453(US10246426, Example 7 | N-[2-(3,4-Difluoro-benzyl)...)
Affinity DataIC50: 6.40nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372463(US10246426, Example 17 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 7.30nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372533(US10246426, Example 91 | 2-(1-Methyl-1H-indol-5-yl...)
Affinity DataIC50: 7.40nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372629(N-[2-(3-Fluoro-4-trifluoromethoxy-benzyl)-2H-[1,2,...)
Affinity DataIC50: 8.80nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372452(US10246426, Example 6 | N-[2-(3,4-Difluoro-benzyl)...)
Affinity DataIC50: 9.5nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372465(US10246426, Example 19 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 9.70nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372473(US10246426, Example 27 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 9.80nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372534(US10246426, Example 92 | 2-(1-Methyl-1H-indazol-5-...)
Affinity DataIC50: 9.90nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372536(US10246426, Example 94 | 2-[6-(3,3-Difluoro-pyrrol...)
Affinity DataIC50: 10nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372477(US10246426, Example 31 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 11nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372637(2-(1,3-Dimethyl-1H-indazol-5-yl)-N-[2-(3-fluoro-4-...)
Affinity DataIC50: 11nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372496(US10246426, Example 52 | N-[2-(4-Fluoro-benzyl)-2H...)
Affinity DataIC50: 12nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372521(US10246426, Example 77 | N-[2-(3,5-Difluoro-4-meth...)
Affinity DataIC50: 13nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372588(US10246426, Example 147 | N-[2-(3,5-Difluoro-4-met...)
Affinity DataIC50: 13nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372622(N-[2-(4-Difluoromethoxy-3-fluoro-benzyl)-2H-[1,2,3...)
Affinity DataIC50: 13nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372581(US10246426, Example 140 | N-[2-(4-Cyano-3-fluoro-b...)
Affinity DataIC50: 14nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372636(2-(1-Ethyl-1H-indazol-5-yl)-N-[2-(3-fluoro-4-trifl...)
Affinity DataIC50: 14nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372462(US10246426, Example 16 | 2-(6-Diethylamino-pyridin...)
Affinity DataIC50: 15nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372464(US10246426, Example 18 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 15nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372468(US10246426, Example 22 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 15nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372535(US10246426, Example 93 | 2-[4-(3-Methyl-oxetan-3-y...)
Affinity DataIC50: 15nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372591(US10246426, Example 150 | N-[2-(3,5-Difluoro-4-met...)
Affinity DataIC50: 16nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372450(US10246426, Example 2 | 2-(4-Dimethylamino-phenyl)...)
Affinity DataIC50: 17nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372460(US10246426, Example 14 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 17nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372476(US10246426, Example 30 | 2-(1-Butyl-1H-indazol-5-y...)
Affinity DataIC50: 17nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372628(N-[2-(3-Fluoro-4-trifluoromethoxy-benzyl)-2H-[1,2,...)
Affinity DataIC50: 17nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372632(2-[6-(3,3-Difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-...)
Affinity DataIC50: 17nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372645(N-[2-(4-Cyano-3-fluoro-benzyl)-2H-[1,2,3]triazol-4...)
Affinity DataIC50: 17nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372480(US10246426, Example 34 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 18nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372485(US10246426, Example 41 | 2-[6-(3,3-Difluoro-pyrrol...)
Affinity DataIC50: 18nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372514(US10246426, Example 70 | N-[2-(4-Cyano-3-fluoro-be...)
Affinity DataIC50: 18nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372605(N-[2-(4-Cyano-3-methyl-benzyl)-2H-[1,2,3]triazol-4...)
Affinity DataIC50: 18nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372472(US10246426, Example 26 | N-[2-(4-Cyano-benzyl)-2H-...)
Affinity DataIC50: 19nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372541(US10246426, Example 99 | N-[2-(4-Cyano-benzyl)-2H-...)
Affinity DataIC50: 19nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372513(US10246426, Example 69 | N-[2-(4-Methyl-benzyl)-2H...)
Affinity DataIC50: 20nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372531(US10246426, Example 89 | N-[2-(4-Difluoromethoxy-b...)
Affinity DataIC50: 20nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372547(US10246426, Example 105 | N-[2-(4-Cyano-3-fluoro-b...)
Affinity DataIC50: 20nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372434(US10246426, Example 1 | N-[2-(4-Fluoro-benzyl)-2H-...)
Affinity DataIC50: 21nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372455(US10246426, Example 9 | 2-(4-Cyclobutoxy-phenyl)-N...)
Affinity DataIC50: 22nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372474(US10246426, Example 28 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 22nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372542(US10246426, Example 100 | N-[2-(4-Cyano-benzyl)-2H...)
Affinity DataIC50: 22nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372607(N-[2-(4-Cyano-3-methyl-benzyl)-2H-[1,2,3]triazol-4...)
Affinity DataIC50: 22nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372611(N-[2-(4-Cyano-3-methyl-benzyl)-2H-[1,2,3]triazol-4...)
Affinity DataIC50: 22nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372619(N-[2-(4-Difluoromethoxy-3-fluoro-benzyl)-2H-[1,2,3...)
Affinity DataIC50: 22nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372456(US10246426, Example 10 | 2-(4-Cyclopropoxy-phenyl)...)
Affinity DataIC50: 23nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372509(US10246426, Example 65 | 2-[6-(3,3-Difluoro-pyrrol...)
Affinity DataIC50: 23nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372527(US10246426, Example 82 | N-[2-(3,5-Difluoro-4-meth...)
Affinity DataIC50: 23nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372638(N-[2-(3-Fluoro-4-trifluoromethoxy-benzyl)-2H-[1,2,...)
Affinity DataIC50: 23nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372479(US10246426, Example 33 | N-[2-(3,4-Difluoro-benzyl...)
Affinity DataIC50: 24nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetVoltage-dependent T-type calcium channel subunit alpha-1H(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM372684(N-[2-(4-Cyano-benzyl)-2H-[1,2,3]triazol-4-yl]-2-[4...)
Affinity DataIC50: 24nMAssay Description:Stock solutions of test compounds are prepared to a concentration of 10 mM in DMSO. For the Cav3.2 assay, serial dilutions of the compounds are prepa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: